Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...

The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care.

Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.

Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE WOODLANDS, Texas, Nov. 08, 2025 ...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., November 07, 2025--Kardigan, a heart health company modernizing cardiovascular ...

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved ...

Pharmaceuticals announced that new sotagliflozin clinical data was presented at the American Heart Association, AHA, Annual ...

High-volume systemic-to-pulmonary ductal shunting occurs frequently in preterm infants and is indicated by diastolic flow reversal in the descending aorta (DAo). We studied the relationship between ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertensi ...

After years of searching for a therapy to combat heart failure with preserved ejection fraction, a research team may have found a breakthrough candidate. Their drug not only improved heart function in ...

Bristol Myers Squibb showcases new long-term and real-world data from cardiovascular portfolio at the AHA scientific sessions 2025: Princeton, New Jersey Wednesday, November 5, 20 ...